公开信息显示，现任基金经理吴兴武先生:中国籍,理学硕士,持有中国证券投资基金业从业证书,曾任摩 根士丹利华鑫基金管理有限公司研究员,广发基金管理有限公司研究发展部、权益投资一部研究员、广 发多元新兴股票型证券投资基金基金经理(自2017年4月25日至2019年4月16日)、广发核心精选混合型证 券投资基金基金经理(自2015年2月17日至2020年2月10日)、广发鑫瑞混合型证券投资基金(LOF)基金经 理(自2019年4月16日至2020年7月29日)、广发再融资主题灵活配置混合型证券投资基金(LOF)基金经理 (自2019年4月16日至2020年7月31日)。现任广发轮动配置混合型证券投资基金基金经理(自2015年2月12 日起任职)、广发医疗保健股票型证券投资基金基金经理(自2018年10月16日起任职)、广发医药健康混合 型证券投资基金基金经理(自2020年10月21日起任职)、广发创新医疗两年持有期混合型证券投资基金基 金经理(自2021年3月19日起任职)。2022年11月4日起任广发竞争优势灵活配置混合型证券投资基金基金 经理。曾任广发主题领先灵活配置混合型证券投资基金基金经理。 截止2024年 ...

Core Viewpoint - The recent performance of the Zhongyin Innovation Medical Mixed A fund shows a decline in net value but strong returns over various time frames, indicating potential resilience in the healthcare investment sector [1]. Fund Performance Summary - The latest net value of Zhongyin Innovation Medical Mixed A is 1.5786 yuan, down by 2.81% - The fund's one-month return is 13.30%, ranking 7 out of 4623 in its category - The three-month return stands at 38.74%, ranking 14 out of 4566 - Year-to-date return is 31.19%, ranking 24 out of 4559 [1]. Holdings Summary - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 70.60%, with the following key positions: - Heng Rui Pharmaceutical: 9.81% - Xinda Bio: 8.55% - Huaneng Pharmaceutical: 8.41% - Kangfang Biotech: 8.35% - Kangnuo Ya-B: 8.32% - Kelun Botai: 7.87% - BeiGene-U: 6.24% - Rongchang Bio: 5.96% - Hansoh Pharmaceutical: 3.98% - Xin Nuo Wei: 3.11% [1]. Fund Manager Background - Zheng Ning, the fund manager, has a master's degree and extensive experience in the investment sector, having previously worked at Taikang Asset Management and Zhonggeng Fund Management - Zheng joined Zhongyin Fund Management in 2022 and has managed multiple funds since then, including the Zhongyin Innovation Medical Mixed Fund [2].

证券代码：002173 证券简称：创新医疗 公告编号：2025-020 创新医疗管理股份有限公司 关于召开 2024 年度现场业绩说明会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假 记载、误导性陈述或者重大遗漏。 创新医疗管理股份有限公司（以下简称"创新医疗"或"公司"）已于 2025 年 4 月 12 日在巨潮资讯网（www.cninfo.com.cn）上披露了《2024 年年度报告》 等相关公告。为做好上市公司投资者关系管理工作，同时便于广大投资者更全面 深入地了解公司 2024 年年度经营情况，公司将举行 2024 年度现场业绩说明会， 就投资者关心的问题进行交流。 一、本次业绩说明会召开的时间、地点 （一）会议召开时间：2025 年 4 月 23 日（星期三）15:00—17:00 （二）会议召开地点：浙江省杭州市上城区城星路 98 号迪凯城星国际 A 座 34 楼创新医疗杭州分公司会议室 二、投资者参加方式 三、公司参会人员 公司董事长陈海军先生、董事游向东先生、总裁马建建先生、董事会秘书郭 1 / 2 立丹女士。同时，公司还邀请了参股企业全诊医学董事长薛翀先生参加本次 ...

Group 1: Event Overview - The 27th Beijing International Science and Technology Expo will be held from May 8 to 11 at the National Convention Center, covering an exhibition area of approximately 50,000 square meters with six major exhibition areas [1] - The exhibition is nearly fully booked with around 800 participating companies and institutions, over 80% of which are specialized and innovative high-tech enterprises at the provincial level or above [1] Group 2: Focus on Medical and Health Industry - The medical and health sector is a key focus of this year's expo, with Beijing positioning it as one of the "dual engines" for innovative development, aiming for an industry scale of 1.06 trillion yuan by 2024, representing an 8.7% year-on-year growth [2] - Beijing has implemented 32 measures to promote innovative pharmaceutical development, significantly reducing drug approval times, such as compressing the review period for supplementary drug applications from 200 days to 60 days [2] Group 3: Technological Innovations in Healthcare - Longmu Valley, a high-end innovative medical device company, will showcase its AI-driven orthopedic surgery robot at the expo, which can reduce surgery time from 2 hours to just 30 minutes [3][4] - The robot utilizes AI for three-dimensional surgical simulations based on pre-operative CT scans, enhancing precision and safety in orthopedic procedures [4] Group 4: Robotics Innovations - The "Tiangong 2.0" humanoid robot will debut at the expo, featuring adaptive walking capabilities for complex terrains and a rapid battery swap system, marking a significant advancement in industrial-grade robotics [5][6] - The upgraded "Tiangong" robot can now navigate stairs and uneven surfaces, with improved running speed and balance, showcasing its versatility for various applications [6][7] Group 5: Investment and Trade Promotion - The expo will also host the 2025 Beijing International Investment and Trade Fair, integrating exhibition and trade promotion activities to facilitate investment discussions and showcase Beijing's technological strengths [8] - The event will feature multiple promotional activities, including a focus on specialized and innovative products from Beijing, aiming to connect local enterprises with international markets [9]

4月12日， 创新医疗 (002173)发布年度报告，公司2024年实现营业收入8.16亿元，同比增长1.30%；归母 净利润亏损9395.40万元，亏损同比扩大174.02%；扣非净利润亏损5957.41万元，亏损同比扩大 112.74%。公司计划不派发现金红利，不送红股，不以公积金转增股本。 作为一家以提供医疗服务为主营业务的上市公司，目前，创新医疗下属有建华医院、康华医院、福恬医 院和明珠医院四家医疗机构。其中，建华医院是三级甲等 综合 性医院，康华医院是二级甲等综合性医 院，福恬医院是二级康复医院，明珠医院是二级甲等综合性医院。 年报指出，国家医疗保障局公布的《2024年医疗保障事业发展统计快报》相关数据显示，与往年相比， 2024年人次均医保支出出现明显下降。报告期内，公司下属医院综合医疗服务的总体收费水平受医保支 付标准的动态调整出现下滑，营业收入未能与门诊量、住院量保持同步增长，主营业务毛利率出现下 滑。 具体来看，2024年，建华医院与北京 同仁堂 中医医院有限责任公司合资成立了同仁堂鹤康（齐齐哈 尔）中医医院有限公司，并进一步加强、深化优势科室与知名院校的紧密合作，当年建华医院（含明珠 医院 ...

最新一期业绩显示，2024年年报，公司实现营业收入8.16亿元，同比1.30%；净利润-93954030.31元，同 比-174.02%，销售毛利率7.81%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)6创新医疗-41.85-41.852.2139.32亿行业平均 46.7942.233.41144.65亿行业中值47.8135.902.5448.88亿1普瑞眼科-191.8123.972.9064.23亿2何氏眼 科-150.9446.281.5229.41亿3迪安诊断-96.3529.011.2689.18亿4光正眼科-90.07214.007.2619.81亿5南华生 物-81.46-107.1912.1430.20亿7国际医学-33.58-32.653.29120.25亿8嘉和美康-27.16-27.162.2840.74亿9皓宸 医疗-22.56-23.234.9021.92亿10美迪西-12.45-12.451.6739.32亿11和元生物-11.58-11.582.0137.64亿 来源：金融界 4月14日，创新医疗今日收盘8.91元，上涨1.60%，最新市净率2.21，总市值39 ...

Policy Developments - The National Healthcare Security Administration has established data working groups across all regions, with the aim of enhancing data governance and transparency in healthcare funding [2] Drug and Device Approvals - Jiangsu Tianshili submitted a listing application for the new drug PXT3003, intended for the treatment of Charcot-Marie-Tooth disease type 1A [4] Capital Markets - Ruijian Pharmaceutical completed nearly 100 million RMB in B+ round financing, bringing total financing to over 200 million RMB in less than six months [6] - Weichan Medical announced the completion of several million RMB in angel round financing, aimed at accelerating product development and market entry [7] - Novartis plans to invest $23 billion in the U.S. over the next five years to enhance production capabilities and ensure the domestic supply of critical medications [8] Industry Events - Boya Bio disclosed plans to sell 80% of its subsidiary, Boya Xinha, to focus on its core blood products business, with an initial listing price of 213 million RMB [10] Financial Reports - Pumen Technology reported a revenue of 1.148 billion RMB for 2024, with a net profit of 345 million RMB, reflecting a 5.12% increase [12] - Huaxi Biotechnology's revenue for 2024 was 5.371 billion RMB, down 11.61%, with a net profit of 174 million RMB, down 70.59% [13] - Watson Bio reported a revenue of 2.821 billion RMB for 2024, down 31.41%, with a net profit of 142 million RMB, down 66.10% [14] - Innovation Medical reported a revenue of 816 million RMB for 2024, with a net loss of 93.95 million RMB [15] - People's Tongtai reported a revenue of 10.048 billion RMB for 2024, down 3.29%, with a net profit of 213 million RMB, down 27% [16] - Haizike reported a revenue of 3.721 billion RMB for 2024, with a net profit of 395 million RMB, up 34% [17] - Hainan Haiyao reported a revenue of approximately 999 million RMB for 2024, down 33%, with a net loss of 1.525 billion RMB [18] - Wantai Bio reported a revenue of approximately 2.245 billion RMB for 2024, down 59.25%, with a net profit of 106 million RMB, down 91.49% [19] Public Opinion Alerts - Xinghao Pharmaceutical announced the resignation of director Li Huiqu due to personal reasons, effective April 11, 2025 [21] - Zhaoyan New Drug acknowledged unusual fluctuations in its stock price, linked to a recent FDA plan that may impact the industry [23]

证券代码：002173 证券简称：创新医疗 公告编号：2025-015 一、重要提示 登录新浪财经APP 搜索【信披】查看更多考评等级 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投资者 应当到证监会指定媒体仔细阅读年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 √不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 二、公司基本情况 1、公司简介 参见2024年年度报告全文"第三节 管理层讨论与分析 二、报告期内公司从事的主要业务"。 3、主要会计数据和财务指标 （1） 近三年主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 单位：元 单位：元 ■ 上述财务指标或其加总数是否与公司已披露季度报告、半年度报告相关财务指标存在重大差异 □是 √否 4、股本及股东情况 （1） 普通股股东和表决权恢复的优先股股东数量及前10名股东持股情况表 ■ 2、报告期主要业务或产品简介 ■ （2） 分季度主要会计数据 单位：股 ■ 持股5%以 ...

创新医疗 管理股份有限公司于2025年4月发布了2024年年度报告。报告显示，公司在营业收入微增的情 况下，净利润却出现大幅下滑，经营活动产生的现金流量净额也显著下降。这些数据的变化，反映出公 司在经营过程中面临着诸多挑战。 营业收入微增1.30% 2024年，创新医疗实现营业收入816,018,808.41元，相较于2023年的805,585,526.56元，增长了1.30%。 从业务构成来看，医疗服务业务是公司的主要收入来源，2024年该业务收入为812,140,358.12元，占营 业收入比重达99.52%，同比增长1.03%。虽然整体营收有所增长，但各地区业务表现存在差异。黑龙江 地区收入491,304,778.60元，同比上升8.82%；浙江地区收入293,767,918.48元，同比下降7.70%；江苏地 区收入30,946,111.33元，同比下降13.61%。这表明公司在不同地区的市场拓展和业务运营效果参差不 齐，部分地区业务面临一定压力。 净利润暴跌174.02% 归属于上市公司股东的净利润为-93,954,030.31元，与2023年的-34,287,743.35元相比，下降了174.02 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.2100 | -0.0800 | -162.5 | -0.1600 | | 每股净资产（元） | 4.03 | 4.16 | -3.13 | 4.2 | | 每股公积金(元) | 6.14 | 6.12 | 0.33 | 6.06 | | 每股未分配利润(元) | -3.17 | -2.90 | -9.31 | -2.80 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 8.16 | 8.06 | 1.24 | 7.1 | | 净利润(亿元) | -0.94 | -0.34 | -176.47 | -0.73 | | 净资产收益率(%) | -5.15 | -1.82 | -182.97 | -3.80 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 15323.08万股，累计占流通股 ...